 Takeda Pharmaceutical Co Ltd NYSE: TAK received a Complete Response Letter CRL from the FDA for its marketing application for TAK-721 budesonide oral suspension for eosinophilic esophagitis EoE, a chronic inflammatory disease of the esophagus. The CRL indicates the FDA has completed its review of the TAK-721 NDA and determined that it cannot be approved in its present form. 